Cidara Therapeutics Inc [CDTX] stock is trading at $19.44, up 1.36%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CDTX shares have gain 13.75% over the last week, with a monthly amount drifted -14.55%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cidara Therapeutics Inc [NASDAQ: CDTX] stock has seen the most recent analyst activity on March 12, 2025, when Citizens JMP initiated its Mkt Outperform rating and assigned the stock a price target of $46. On December 13, 2024, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $34 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $33 on November 08, 2024. H.C. Wainwright upgraded its rating to a Buy but $24 remained the price target by the analyst firm on August 14, 2024. In a note dated September 22, 2021, WBB Securities upgraded an Strong Buy rating on this stock but restated the target price of $6.25.
Cidara Therapeutics Inc [CDTX] stock has fluctuated between $10.00 and $28.42 over the past year. Currently, Wall Street analysts expect the stock to reach $46 within the next 12 months. Cidara Therapeutics Inc [NASDAQ: CDTX] shares were valued at $19.44 at the most recent close of the market. An investor can expect a potential return of 136.63% based on the average CDTX price forecast.
Analyzing the CDTX fundamentals
Cidara Therapeutics Inc [NASDAQ:CDTX] reported sales of 8.77M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -10.65%, Pretax Profit Margin comes in at -19.67%, and Net Profit Margin reading is -19.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.78, Equity is -1.71 and Total Capital is -0.57. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.89 points at the first support level, and at 18.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.78, and for the 2nd resistance point, it is at 20.13.
Ratios To Look Out For
For context, Cidara Therapeutics Inc’s Current Ratio is 4.25. In addition, the Quick Ratio stands at 4.25 and the Cash Ratio stands at 3.83. Considering the valuation of this stock, the price to sales ratio is 24.28, the price to book ratio is 1.30.
Transactions by insiders
Recent insider trading involved Ward Shane, COO & CLO, that happened on Mar 11 ’25 when 1664.0 shares were sold. CHIEF SCIENTIFIC OFFICER, Tari Leslie completed a deal on Mar 11 ’25 to sell 1773.0 shares. Meanwhile, Chief Medical Officer Sandison Taylor sold 924.0 shares on Sep 11 ’24.
